NRAS and neoplasm: Importantly, NF1 mutations have been found in melanomas that lack both BRAF and NRAS mutations, with 25–30% of such melanomas found to harbour deleterious NF1 mutations, thus implying that NF1 inactivation has conferred aberrant MAPK pathway activation in these tumours [50, 51].